Past, present and future of Estetrol (E4); a natural fetal estrogen for human use

Estetrol (E4) is a natural estrogen produced by the fetal liver with a distinctive pharmacologic profile separating it from other natural and synthetic estrogens. Encompassing 25 years of research and development, this review summarizes the history, biochemistry, pharmacology, clinical development, and potential future applications of E4. Essential features of E4 are (1) its high oral bioavailability, long half-life and minimal binding to sex hormone-binding globulin (SHBG), enabling once-daily oral use, and (2) the limited effects on liver function, especially on hemostatic factors, resulting in a lower risk of venous thromboembolism compared to other natural and synthetic estrogens. Estetrol is further characterized as a natural estrogen with selective tissue activity, with a limited impact on breast tissue and cardiovascular and metabolic parameters, while preserving efficacy including bone mass protection. Estetrol therefore has the potential for a markedly improved safety profile. Clinically, the E4/drospirenone (DRSP) combined oral contraceptive (COC) is available worldwide since 2022 and provides effective contraception, a predictable bleeding profile, and a favorable tolerability profile. In phase 2 and 3 studies in postmenopausal women, oral E4 improves vasomotor symptoms, vaginal and urogenital complaints, and quality of life and wellbeing. Ongoing research is exploring wider uses, including combination with the oral GnRH antagonist relugolix for a COC with a focus on the perimenopausal transition and possible applications of E4 in gynecology, endocrinology, obstetrics, neurology and oncology, especially the treatment of advanced breast and prostate cancer.

Authors

Institutions

Publication Details

Journal
Endocrine Reviews
Published
2026-11-21
DOI
https://doi.org/10.1210/endrev/bnag045
Primary Topic
Estrogen and related hormone effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Past, present and future of Estetrol (E4); a natural fetal estrogen for human use

Kristina Gemzell‐Danielsson, Herjan J.T. Coelingh Bennink, Frank Z. Stanczyk, Karolina Afors et al.
Endocrine Reviews
Estrogen and related hormone effects
article

Past, present and future of Estetrol (E4); a natural fetal estrogen for human use

Kristina Gemzell‐Danielsson, Herjan J.T. Coelingh Bennink, Frank Z. Stanczyk, Karolina Afors, Carolyn L. Westhoff, Alessandra Graziottin, Giuseppe Benagiano, Jonathan Douxfils
article en

Abstract

Estetrol (E4) is a natural estrogen produced by the fetal liver with a distinctive pharmacologic profile separating it from other natural and synthetic estrogens. Encompassing 25 years of research and development, this review summarizes the history, biochemistry, pharmacology, clinical development, and potential future applications of E4. Essential features of E4 are (1) its high oral bioavailability, long half-life and minimal binding to sex hormone-binding globulin (SHBG), enabling once-daily oral use, and (2) the limited effects on liver function, especially on hemostatic factors, resulting in a lower risk of venous thromboembolism compared to other natural and synthetic estrogens. Estetrol is further characterized as a natural estrogen with selective tissue activity, with a limited impact on breast tissue and cardiovascular and metabolic parameters, while preserving efficacy including bone mass protection. Estetrol therefore has the potential for a markedly improved safety profile. Clinically, the E4/drospirenone (DRSP) combined oral contraceptive (COC) is available worldwide since 2022 and provides effective contraception, a predictable bleeding profile, and a favorable tolerability profile. In phase 2 and 3 studies in postmenopausal women, oral E4 improves vasomotor symptoms, vaginal and urogenital complaints, and quality of life and wellbeing. Ongoing research is exploring wider uses, including combination with the oral GnRH antagonist relugolix for a COC with a focus on the perimenopausal transition and possible applications of E4 in gynecology, endocrinology, obstetrics, neurology and oncology, especially the treatment of advanced breast and prostate cancer.

Endocrine Reviews
University of Southern California (US), University of Verona (IT), University College Hospital (GB), Karolinska University Hospital (SE), University of Namur (BE), Columbia University Irving Medical Center (US), Karolinska Institutet (SE), Sapienza University of Rome (IT)
Estrogen and related hormone effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon